Skip to main content

Table 1 Clinical and virological parameters

From: Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

Patient ID Age a Sex b Plasma HIV RNA Load (copies/ml) HIV-1 Subtype c Treatment History d AfriPOLA DEEPGEN
DR-0091-08 2 F 120 750 D AZT/3TC/NVP
DR-0119-08 15 F 203 550 A D4T/3TC/EFV
DR-0130-08 46 F 19 612 A AZT/3TC/NVP
DR-0245-08 46 M 8052 D AZT/3TC/NVP
DR-0292-08 61 M 29 374 C AZT/3TC/EFV
DR-0303-08 8 M 76 044 D AZT/3TC/NVP
DR-0370-08 43 F 50 353 A AZT/3TC/NVP
DR-0321-09 32 F 4436 D AZT/3TC/NVP
DR-0019-11 13 F 10 018 A AZT/3TC/NVP
DR-0024-11 18 M 5426 D AZT/3TC/NVP
DR-0109-08 16 F 28 354 C d4T/3TC/EFV  
DR-0116-08 2 F 15 903 CRF01_AE AZT/3TC/NVP  
DR-0118-08 11 M 216 996 D d4T/3TC/NVP  
DR-0143-08 34 M 125 575 A d4T/3TC/EFV  
DR-0224-08 46 F 3151 D AZT/3TC/EFV  
DR-0308-08 3 M 138 721 D d4T/3TC/NVP  
DR-0330-08 46 F 7989 A d4T/3TC/NVP  
DR-0344-08 3 M 138 721 D d4T/3TC/NVP  
DR-0357-08 37 F 44 876 nr AZT/3TC/EFV  
DR-0385-08 Unk F 12 836 A AZT/3TC/NVP  
DR-0005-09 60 M 5109 D AZT/3TC/NVP  
DR-0009-09 29 F 90 781 B AZT/3TC/NVP  
DR-0056-09 17 M 41 538 A AZT/3TC/EFV  
DR-0130-09 18 M 35 136 CRF01_AE AZT/3TC/EFV  
DR-0194-09 3 F 6789 D d4T/3TC/NVP  
DR-0201-09 2 F 34 162 A AZT/3TC/NVP  
DR-0295-09 10 F 10 407 A AZT/3TC/NVP  
DR-0008-10 11 M 4226 A AZT/3TC/EFV  
DR-0019-10 6 F 3108 D AZT/3TC/EFV  
DR-0073-10 14 F 4896 A AZT/3TC/EFV  
DR-0075-10 12 M 11 680 A AZT/3TC/EFV  
DR-0077-10 53 F Unk A d4T/3TC/EFV  
DR-0095-10 18 F 9254 D AZT/3TC/EFV  
DR-0122-10 13 F 580 870 A AZT/3TC/EFV  
DR-0141-11 19 M 2946 A AZT/3TC/EFV  
DR-0064-10 Unk M 110 000 D TDF/3TC/NVP
DR-0111-09 49 F 5573 CRF01_AE TDF/FTC/LPV-RTV
DR-0372-08 44 M 60 114 nr TDF/FTC/NVP
DR-0242-08 Unk F 199 519 nr TDF/FTC/EFV
DR-0142-08 17 F 513 016 A ABC/3TC/EFV
DR-0272-09 12 Unk 34 174 D Unk  
DR-0279-08 30 M 994 576 A TDF/FTC/EFV  
DR-0023-09 57 M 154 226 D TDF/3TC/EFV  
DR-0358-08 48 Unk Unk D ddI/EFV/LPV-RTV  
DR-0254-08 48 F 1983 A TDF/3TC/LPV-RTV  
DR-0319-08 34 M 193 656 D TDF/FTC/NVP  
DR-0141-08 3 M 106 478 D ABC/3TC/NVP  
DR-0230-08 10 F 7256 A ABC/3TC/EFV  
DR-0124-10 7 M 165 008 D ABC/3TC/NVP  
DR-0085-11 38 M 70 218 D TDF/FTC/NVP  
  1. a Age in years-old when known. Unk, unknown
  2. b M, male; F, female
  3. c HIV-1 subtype determined using HIV-1 reverse transcriptase (Sanger) sequences as described [13]
  4. d Antiretroviral treatment history: zidovudine, AZT; didanosine, ddI; stavudine, d4T; lamivudine, 3TC; abacavir, ABC; tenofovir, TDF; emtricitabine, FTC; nevirapine, NVP; efavirenz, EFV; ritonavir, RTV; and enfuvirtide, T-20. Unk, unknown; n.d., not determined